Economics and management in the biopharmaceutical industry in the USA: evolution and strategic change
"From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers....
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
London
Routledge
2019
|
| Schriftenreihe: | Routledge studies in the economics of business and industry
Routledge studies in the economics of business and industry 4 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | "From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry's main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those eager to learn about this dynamic, fast-evolving industry"-- |
| Beschreibung: | Description based on print version record; title from PDF title page, viewed (06/10/2020) |
| Beschreibung: | 1 online resource |
| ISBN: | 9781351012713 1351012711 9781351012690 135101269X |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047014318 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 201118s2019 |||| o||u| ||||||eng d | ||
| 020 | |a 9781351012713 |9 978-1-351-01271-3 | ||
| 020 | |a 1351012711 |9 1-351-01271-1 | ||
| 020 | |a 9781351012690 |9 978-1-351-01269-0 | ||
| 020 | |a 135101269X |9 1-351-01269-X | ||
| 035 | |a (ZDB-7-TFC)9781351012713 | ||
| 035 | |a (DE-599)BVBBV047014318 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 338.4/76151900973 |2 23 | |
| 100 | 1 | |a Kim, Rachel |d 1970- |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Economics and management in the biopharmaceutical industry in the USA |b evolution and strategic change |c Rachel Kim |
| 264 | 1 | |a London |b Routledge |c 2019 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Routledge studies in the economics of business and industry | |
| 490 | 0 | |a Routledge studies in the economics of business and industry |v 4 | |
| 500 | |a Description based on print version record; title from PDF title page, viewed (06/10/2020) | ||
| 520 | |a "From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry's main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those eager to learn about this dynamic, fast-evolving industry"-- | ||
| 650 | 4 | |a Pharmaceutical biotechnology industry / United States / History | |
| 650 | 4 | |a Pharmaceutical biotechnology / United States / History | |
| 856 | 4 | 0 | |u https://www.taylorfrancis.com/books/9781351012713 |x Verlag |z URL des Erstveroeffentlichers |3 Volltext |
| 912 | |a ZDB-7-TFC | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032421855 | ||
Datensatz im Suchindex
| _version_ | 1804181973638316032 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Kim, Rachel 1970- |
| author_facet | Kim, Rachel 1970- |
| author_role | aut |
| author_sort | Kim, Rachel 1970- |
| author_variant | r k rk |
| building | Verbundindex |
| bvnumber | BV047014318 |
| collection | ZDB-7-TFC |
| ctrlnum | (ZDB-7-TFC)9781351012713 (DE-599)BVBBV047014318 |
| dewey-full | 338.4/76151900973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151900973 |
| dewey-search | 338.4/76151900973 |
| dewey-sort | 3338.4 1176151900973 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03192nmm a2200385zc 4500</leader><controlfield tag="001">BV047014318</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">201118s2019 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781351012713</subfield><subfield code="9">978-1-351-01271-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1351012711</subfield><subfield code="9">1-351-01271-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781351012690</subfield><subfield code="9">978-1-351-01269-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">135101269X</subfield><subfield code="9">1-351-01269-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-7-TFC)9781351012713</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047014318</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151900973</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kim, Rachel</subfield><subfield code="d">1970-</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Economics and management in the biopharmaceutical industry in the USA</subfield><subfield code="b">evolution and strategic change</subfield><subfield code="c">Rachel Kim</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London</subfield><subfield code="b">Routledge</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Routledge studies in the economics of business and industry</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Routledge studies in the economics of business and industry</subfield><subfield code="v">4</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on print version record; title from PDF title page, viewed (06/10/2020)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry's main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those eager to learn about this dynamic, fast-evolving industry"--</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical biotechnology industry / United States / History</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical biotechnology / United States / History</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.taylorfrancis.com/books/9781351012713</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveroeffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-7-TFC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032421855</subfield></datafield></record></collection> |
| id | DE-604.BV047014318 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T15:58:14Z |
| indexdate | 2024-07-10T09:00:10Z |
| institution | BVB |
| isbn | 9781351012713 1351012711 9781351012690 135101269X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032421855 |
| open_access_boolean | |
| physical | 1 online resource |
| psigel | ZDB-7-TFC |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| publisher | Routledge |
| record_format | marc |
| series2 | Routledge studies in the economics of business and industry |
| spelling | Kim, Rachel 1970- Verfasser aut Economics and management in the biopharmaceutical industry in the USA evolution and strategic change Rachel Kim London Routledge 2019 1 online resource txt rdacontent c rdamedia cr rdacarrier Routledge studies in the economics of business and industry Routledge studies in the economics of business and industry 4 Description based on print version record; title from PDF title page, viewed (06/10/2020) "From a managerial perspective, the biopharmaceutical industry represents a competitive, fast-changing, intellectually-powered, innovation-driven sector. Many management scholars have studied this discontinuous era to make sense of strategic behavior and the cognition of firms and top managers. A past look at the biopharmaceutical industry provides answers to questions that most managers have. For example, what options do you have and what actions do you take when new firms enter your industry? In the 1970s, new biotechnology firms, funded by venture capitalists, appeared in the pharmaceutical industry with new knowledge. Successful pharmaceutical firms decided to collaborate with the new entrants and forge relationships to develop and create new, biotechnology engineered drugs. Thus, the addition of new biotechnology firms ushered in a new business model based on strategic alliances. Strategic alliances have now become an industrial norm called open innovation. The author looks at the historical path of the biopharmaceutical industry, particularly in the United States. While the pharmaceutical industry's main contributions to society are substantial, there are pressing challenges the industry must face, such as an increase in infectious disease outbreaks or the global aging population, which require new types of care, additionally, mental health care and prescription painkiller addiction are persistent issues with economic repercussions to both federal and local governments. This book presents a holistic view of the biopharmaceutical industry, putting it in a historical context. It will best serve those eager to learn about this dynamic, fast-evolving industry"-- Pharmaceutical biotechnology industry / United States / History Pharmaceutical biotechnology / United States / History https://www.taylorfrancis.com/books/9781351012713 Verlag URL des Erstveroeffentlichers Volltext |
| spellingShingle | Kim, Rachel 1970- Economics and management in the biopharmaceutical industry in the USA evolution and strategic change Pharmaceutical biotechnology industry / United States / History Pharmaceutical biotechnology / United States / History |
| title | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change |
| title_auth | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change |
| title_exact_search | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change |
| title_exact_search_txtP | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change |
| title_full | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change Rachel Kim |
| title_fullStr | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change Rachel Kim |
| title_full_unstemmed | Economics and management in the biopharmaceutical industry in the USA evolution and strategic change Rachel Kim |
| title_short | Economics and management in the biopharmaceutical industry in the USA |
| title_sort | economics and management in the biopharmaceutical industry in the usa evolution and strategic change |
| title_sub | evolution and strategic change |
| topic | Pharmaceutical biotechnology industry / United States / History Pharmaceutical biotechnology / United States / History |
| topic_facet | Pharmaceutical biotechnology industry / United States / History Pharmaceutical biotechnology / United States / History |
| url | https://www.taylorfrancis.com/books/9781351012713 |
| work_keys_str_mv | AT kimrachel economicsandmanagementinthebiopharmaceuticalindustryintheusaevolutionandstrategicchange |